103 related articles for article (PubMed ID: 18771567)
1. Subcutaneous lipoatrophy induced by long-term pegvisomant administration.
Salvatore C; Giovanni R; Vittorio C; Claudio S; Patrizia CS
Clin Endocrinol (Oxf); 2009 Apr; 70(4):655-6. PubMed ID: 18771567
[No Abstract] [Full Text] [Related]
2. Pegvisomant-induced lipohypertrophy: report of a case with histopathology.
Marazuela M; Daudén E; Ocón E; Moure D; Nattero L
Ann Intern Med; 2007 Nov; 147(10):741-3. PubMed ID: 18025453
[No Abstract] [Full Text] [Related]
3. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant.
Maffei P; Martini C; Pagano C; Sicolo N; Corbetti F
Ann Intern Med; 2006 Aug; 145(4):310-2. PubMed ID: 16908925
[No Abstract] [Full Text] [Related]
4. Lipodystrophy during pegvisomant therapy: a case report and review of the literature.
Buyuktas D; Celik O; Kantarci F; Kadioglu P
Clinics (Sao Paulo); 2010; 65(9):931-3. PubMed ID: 21049223
[No Abstract] [Full Text] [Related]
5. Lipodystrophy in patients with acromegaly receiving pegvisomant.
Bonert VS; Kennedy L; Petersenn S; Barkan A; Carmichael J; Melmed S
J Clin Endocrinol Metab; 2008 Sep; 93(9):3515-8. PubMed ID: 18611977
[TBL] [Abstract][Full Text] [Related]
6. ACROSTUDY: Status Update on 469 Patients.
Brue T
Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
[TBL] [Abstract][Full Text] [Related]
7. Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly.
Atmaca A; Erbas T
Exp Clin Endocrinol Diabetes; 2005 Jun; 113(6):340-3. PubMed ID: 15977102
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
9. [Growth hormone-receptor antagonist pegvisomant].
Herrmann BL; Strasburger CJ
Dtsch Med Wochenschr; 2004 Oct; 129(44):2356-8. PubMed ID: 15497105
[No Abstract] [Full Text] [Related]
10. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of pegvisomant in patients with acromegaly.
Hodish I; Barkan A
Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):324-32. PubMed ID: 18431372
[TBL] [Abstract][Full Text] [Related]
12. Pegvisomant (Somavert) for acromegaly.
Med Lett Drugs Ther; 2003 Jul; 45(1160):55-6. PubMed ID: 12840714
[No Abstract] [Full Text] [Related]
13. Lessons from 6 years of GH receptor antagonist therapy for acromegaly.
Trainer PJ
J Endocrinol Invest; 2003; 26(10 Suppl):44-52. PubMed ID: 15497659
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
15. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
[TBL] [Abstract][Full Text] [Related]
16. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
17. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
Jehle S; Reyes CM; Sundeen RE; Freda PU
J Clin Endocrinol Metab; 2005 Mar; 90(3):1588-93. PubMed ID: 15585549
[TBL] [Abstract][Full Text] [Related]
18. Place of pegvisomant in acromegaly.
Ho KK
Lancet; 2001 Nov; 358(9295):1743-4. PubMed ID: 11734225
[No Abstract] [Full Text] [Related]
19. DPT vaccine-induced lipoatrophy: an observational study.
Sardana K; Garg VK; Bhushan P; Relhan V; Sharma S
Int J Dermatol; 2007 Oct; 46(10):1050-4. PubMed ID: 17910713
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant.
Feenstra J; van Aken MO; de Herder WW; Feelders RA; van der Lely AJ
Eur J Endocrinol; 2006 Jun; 154(6):805-6. PubMed ID: 16728538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
